mdanderson.org
Jun 23, 2024, 05:10
Yan Leyfman: Pioneering work that is enhancing NK CAR efficacy
Yan Leyfman, Internal Medicine and Clinical Researcher at Icahn School of Medicine at Mount Sinai, shared a post on LinkedIn:
“Pioneering work that is enhancing NK CAR efficacy.
Authors showed that the incorporation of CD28 costimulation, which is normally absent in NK cells, in the CAR construct improves efficacy of CAR NK cells via the LCK/CD3ζ/ZAP70 pathway.
Congratulations to Katy Rezvani and team on the pioneering work.”
Additional information.
Source: Yan Leyfman/LinkedIn
Alexander Biederstadt
Ali Rezvan
Ana Karen. Nunez Cortes
Antrix Jain
Bijender Kumar
Bin Liu
cancer
CD28
Chenyu Zhang
David Marin
Elizabeth J. Shpall
Emily Ensley
Enli Liu
Francia Reyes-Silva
Francisco Vega
Gary M. Deyter
Hind Rafei
Icahn School of Medicine
Janos Roszik
Joseph D. Khoury
Katayoun Rezvani
Katy Rezvani
Ken Chen
Kiran Kundu
Kun Hee Kim
LCK/CD3ζ/ZAP70 pathway
Luciana Melo Garcia
Luis Muniz-Feliciano
Luisa M. Solis Soto
Maria Gabriela Raso
May Daher
Mayra Shanley
Mecit Kaplan
Melisa J. Montalvo
Mohsen Fathi
Nadima Uprety
Natalie W. Fowlkes
Navin Varadarajan
NK CAR
NK cells
OncoDaily
Oncology
Paul Lin
Pei Lin
Pinaki P. Banerjee
Ping Li
Rafet Basar
Rejeena Shrestha
Sophia L. Cha
Sunil Acharya
Vakul Mohanty
Xianli Jiang
Xin Ru Jiang
Xingliang Guo
Yan Leyfman
Ye Li
Yuchen Pan
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19